Light chain variable region gene usage in light chain amyloidosis (AL) determines the organs preferentially affected by amyloid deposition (organ tropism). Specifically, the V lambda II subtype of AL light chains is associated with early and predominant cardiac involvement and poorer overall survival. The mechanism by which organ tropism may be responsible for the inter-individual variations in clinical presentation and prognosis remains unclear. The primary objective of this grant application is to determine whether specific, clonal light chain variable region genes influence the nature and extent of cardiac dysfunction, and the change in cardiac function in response to therapy. In keeping with stated objectives of the R21 program, we plan to generate meaningful new data from a well-characterized group of human subjects in a large volume Amyloid clinic (> 120 AL patients yearly), by combining novel, sensitive, well-validated imaging techniques with analysis of existing biological specimens. This proposal is the result of a new, synergistic collaboration between cardiac imaging, basic and clinical immunology, and clinical amyloidosis investigators.
Specific Aims : 1) To evaluate the influence of the V lambda II subtype on the presence and severity of systolic and diastolic function in AL, 2) To evaluate whether the V lambda II subtype influences changes in systolic and diastolic function after high dose chemotherapy and peripheral blood stem cell transplant. Echocardiography and bone marrow samples are available in 50 AL patients. The R21 mechanism would be used to fund clonal light chain variable region gene analysis from bone marrow samples in this group. To increase sample size, we will supplement the existing database by prospectively enrolling an additional 30 patients. We will use novel, sensitive imaging (tissue Doppler strain) to quantify regional and global cardiac function, and highly sensitive biochemical techniques (nephelometry), to quantify changes in clonal burden, before and after therapy. All patients have detailed characterization of hematologic, renal and hepatic function. This exploratory effort seeks to exploit a unique clinical environment to generate pilot data that will be used to design hypothesis-based proposals for larger and longer-term clinical trials. The long-term goal of this research is to better understand the factors that influence the development of cardiac dysfunction in AL with the aim of optimizing treatment strategies to improve clinical outcomes in AL patients. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL076513-01
Application #
6751827
Study Section
Special Emphasis Panel (ZRG1-CCVS (01))
Program Officer
Massicot-Fisher, Judith
Project Start
2004-09-20
Project End
2006-08-31
Budget Start
2004-09-20
Budget End
2005-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$132,361
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bellavia, Diego; Abraham, Roshini S; Pellikka, Patricia A et al. (2011) Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al) J Am Soc Echocardiogr 24:444-54
Abraham, Theodore P; Liang, Hsin-Yueh (2009) Stress echocardiography: diastole to the rescue. J Am Coll Cardiol 53:706-8
Abraham, Theodore P; Pinheiro, Aurelio C (2008) Speckle-derived strain a better tool for quantification of stress echocardiography? J Am Coll Cardiol 51:158-60
Abraham, Theodore P; Dimaano, Veronica L; Liang, Hsin-Yueh (2007) Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation 116:2597-609
Modesto, Karen M; Dispenzieri, Angela; Gertz, Morie et al. (2007) Vascular abnormalities in primary amyloidosis. Eur Heart J 28:1019-24